Symbols / PSNL Stock $5.98 -5.23% Personalis, Inc.
PSNL (Stock) Chart
About
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives. Its services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and for clinical trials, as well as tests are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection. The company's customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and cancer patients. The company has strategic collaboration with Tempus AI, Inc. to bring testing to colorectal cancer patients. Personalis, Inc. was incorporated in 2011 and is headquartered in Fremont, California.
Stock Fundamentals
Scroll to Statements| Market Cap | 625.97M | Enterprise Value | 464.29M | Income | -81.27M | Sales | 69.65M | Book/sh | 2.55 | Cash/sh | 2.29 |
| Dividend Yield | — | Payout | 0.00% | Employees | 259 | IPO | — | P/E | — | Forward P/E | -6.33 |
| PEG | — | P/S | 8.99 | P/B | 2.35 | P/C | — | EV/EBITDA | -5.95 | EV/Sales | 6.67 |
| Quick Ratio | 6.46 | Current Ratio | 6.76 | Debt/Eq | 16.85 | LT Debt/Eq | — | EPS (ttm) | -0.91 | EPS next Y | -0.94 |
| EPS Growth | — | Revenue Growth | 3.20% | Earnings | 2026-05-05 | ROA | -18.21% | ROE | -35.02% | ROIC | — |
| Gross Margin | 22.65% | Oper. Margin | -145.67% | Profit Margin | -116.69% | Shs Outstand | 104.68M | Shs Float | 68.17M | Short Float | 17.74% |
| Short Ratio | 6.95 | Short Interest | — | 52W High | 11.50 | 52W Low | 3.62 | Beta | 2.21 | Avg Volume | 1.47M |
| Volume | 624.83K | Target Price | $11.29 | Recom | Strong_buy | Prev Close | $6.31 | Price | $5.98 | Change | -5.23% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-05 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $10 |
| 2026-02-27 | main | Needham | Buy → Buy | $12 |
| 2026-02-11 | main | BTIG | Buy → Buy | $13 |
| 2026-01-26 | main | Guggenheim | Buy → Buy | $13 |
| 2026-01-09 | reit | BTIG | Buy → Buy | $12 |
| 2025-12-02 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $11 |
| 2025-11-11 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $9 |
| 2025-11-11 | main | Guggenheim | Buy → Buy | $12 |
| 2025-11-11 | main | HC Wainwright & Co. | Buy → Buy | $13 |
| 2025-11-11 | main | BTIG | Buy → Buy | $12 |
| 2025-11-06 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-11-05 | main | Needham | Buy → Buy | $10 |
| 2025-10-22 | main | BTIG | Buy → Buy | $11 |
| 2025-09-08 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2025-08-06 | main | HC Wainwright & Co. | Buy → Buy | $9 |
| 2025-05-07 | main | HC Wainwright & Co. | Buy → Buy | $9 |
| 2025-04-10 | reit | Needham | Buy → Buy | $7 |
| 2025-03-17 | init | Craig-Hallum | — → Buy | $8 |
| 2025-02-28 | main | Needham | Buy → Buy | $7 |
| 2025-02-28 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
- This cancer-monitoring test tracked relapse and resistance in 10,000 patients - Stock Titan ue, 21 Apr 2026 10
- $PSNL stock is down 16% today. Here's what we see in our data. - Quiver Quantitative hu, 12 Mar 2026 07
- InvestingPro’s Fair Value predicted 40% drop in Personalis stock By Investing.com - Investing.com ue, 21 Apr 2026 11
- Personalis, Inc. (PSNL) Stock Analysis: A Promising 14.46% Upside Potential Amid Strategic Collaboration - DirectorsTalk Interviews Fri, 16 Jan 2026 08
- Personalis, Inc. (PSNL): A Bull Case Theory - Yahoo Finance Mon, 02 Feb 2026 08
- Personalis Stock Pre-Market (-5.3%): FY26 Guidance Overshadows Q4 EPS Beat - Trefis Fri, 06 Mar 2026 08
- Is Personalis (PSNL) Stock Risky Now | Price at $6.61, Up 0.46% - Analyst Upgrade - Cổng thông tin điện tử Tỉnh Sơn La Mon, 06 Apr 2026 07
- $PSNL stock is up 13% today. Here's what we see in our data. - Quiver Quantitative hu, 22 Jan 2026 08
- Personalis adds a blood-test feature to track cancer drug resistance - Stock Titan Mon, 13 Apr 2026 07
- Personalis, Inc. (PSNL) Stock Analysis: Exploring a Promising 24.98% Upside with Innovative Cancer Genomics - DirectorsTalk Interviews Fri, 27 Feb 2026 08
- Personalis, Inc. (NASDAQ:PSNL) Just Reported And Analysts Have Been Lifting Their Price Targets - Yahoo Finance Fri, 07 Nov 2025 08
- Personalis Stock Pre-Market (-4.0%): Downgrade Cites Competitive Headwinds - Trefis ue, 13 Jan 2026 08
- Personalis executives to appear at Needham virtual conference Apr. 15 - Stock Titan Wed, 01 Apr 2026 07
- Personalis, Inc. (PSNL) Stock Analysis: A 11.76% Potential Upside Amidst Revenue Challenges - DirectorsTalk Interviews Fri, 30 Jan 2026 08
- Personalis (PSNL) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance hu, 26 Feb 2026 08
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
69.65
-17.69%
|
84.61
+15.15%
|
73.48
+12.97%
|
65.05
|
| Operating Revenue |
|
68.33
-19.13%
|
84.49
+15.61%
|
73.08
+13.07%
|
64.64
|
| Cost Of Revenue |
|
53.87
-6.78%
|
57.79
+4.55%
|
55.27
+6.92%
|
51.70
|
| Reconciled Cost Of Revenue |
|
53.87
-6.78%
|
57.79
+4.55%
|
55.27
+6.92%
|
51.70
|
| Gross Profit |
|
15.78
-41.19%
|
26.82
+47.33%
|
18.21
+36.39%
|
13.35
|
| Operating Expense |
|
103.83
+9.19%
|
95.09
-16.95%
|
114.50
-11.16%
|
128.88
|
| Research And Development |
|
50.26
+2.78%
|
48.91
-24.50%
|
64.78
-0.21%
|
64.91
|
| Selling General And Administration |
|
53.57
+15.99%
|
46.19
-7.12%
|
49.73
-22.27%
|
63.97
|
| Total Expenses |
|
157.71
+3.16%
|
152.88
-9.95%
|
169.78
-5.98%
|
180.58
|
| Operating Income |
|
-88.06
-28.99%
|
-68.27
+29.11%
|
-96.29
+16.65%
|
-115.53
|
| Total Operating Income As Reported |
|
-88.06
-28.99%
|
-68.27
+37.90%
|
-109.94
+4.84%
|
-115.53
|
| EBITDA |
|
-71.00
-0.99%
|
-70.30
+27.38%
|
-96.81
+7.49%
|
-104.64
|
| Normalized EBITDA |
|
-71.00
-0.99%
|
-70.30
+15.47%
|
-83.17
+20.52%
|
-104.64
|
| Reconciled Depreciation |
|
10.05
-8.18%
|
10.94
-3.14%
|
11.30
+33.97%
|
8.43
|
| EBIT |
|
-81.04
+0.24%
|
-81.24
+24.85%
|
-108.10
+4.40%
|
-113.07
|
| Total Unusual Items |
|
—
|
0.00
+100.00%
|
-13.64
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
—
|
0.00
+100.00%
|
-13.64
|
0.00
|
| Special Income Charges |
|
—
|
0.00
+100.00%
|
-13.64
|
0.00
|
| Impairment Of Capital Assets |
|
—
|
0.00
-100.00%
|
5.57
|
0.00
|
| Restructuring And Mergern Acquisition |
|
—
|
0.00
-100.00%
|
8.08
|
0.00
|
| Net Income |
|
-81.27
+0.02%
|
-81.28
+24.94%
|
-108.30
+4.43%
|
-113.31
|
| Pretax Income |
|
-81.25
+0.02%
|
-81.27
+24.90%
|
-108.21
+4.47%
|
-113.28
|
| Net Non Operating Interest Income Expense |
|
6.95
+26.69%
|
5.49
-5.27%
|
5.79
+163.83%
|
2.19
|
| Interest Expense Non Operating |
|
0.20
+754.17%
|
0.02
-78.18%
|
0.11
-45.27%
|
0.20
|
| Net Interest Income |
|
6.95
+26.69%
|
5.49
-5.27%
|
5.79
+163.83%
|
2.19
|
| Interest Expense |
|
0.20
+754.17%
|
0.02
-78.18%
|
0.11
-45.27%
|
0.20
|
| Interest Income Non Operating |
|
7.16
+29.85%
|
5.51
-6.63%
|
5.90
+146.29%
|
2.40
|
| Interest Income |
|
7.16
+29.85%
|
5.51
-6.63%
|
5.90
+146.29%
|
2.40
|
| Other Income Expense |
|
-0.14
+99.23%
|
-18.48
-4.38%
|
-17.71
-29132.79%
|
0.06
|
| Other Non Operating Income Expenses |
|
-0.14
+99.23%
|
-18.48
-354.40%
|
-4.07
-6768.85%
|
0.06
|
| Tax Provision |
|
0.02
+16.67%
|
0.02
-78.31%
|
0.08
+107.50%
|
0.04
|
| Tax Rate For Calcs |
|
0.00
-100.00%
|
0.00
|
0.00
-100.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-81.27
+0.02%
|
-81.28
+24.94%
|
-108.30
+4.43%
|
-113.31
|
| Net Income From Continuing Operation Net Minority Interest |
|
-81.27
+0.02%
|
-81.28
+24.94%
|
-108.30
+4.43%
|
-113.31
|
| Net Income From Continuing And Discontinued Operation |
|
-81.27
+0.02%
|
-81.28
+24.94%
|
-108.30
+4.43%
|
-113.31
|
| Net Income Continuous Operations |
|
-81.27
+0.02%
|
-81.28
+24.94%
|
-108.30
+4.43%
|
-113.31
|
| Normalized Income |
|
-81.27
+0.02%
|
-81.28
+14.13%
|
-94.65
+16.47%
|
-113.31
|
| Net Income Common Stockholders |
|
-81.27
+0.02%
|
-81.28
+24.94%
|
-108.30
+4.43%
|
-113.31
|
| Diluted EPS |
|
—
|
-1.37
+39.11%
|
-2.25
+9.27%
|
-2.48
|
| Basic EPS |
|
—
|
-1.37
+39.11%
|
-2.25
+9.27%
|
-2.48
|
| Basic Average Shares |
|
—
|
59.25
+22.99%
|
48.18
+5.41%
|
45.70
|
| Diluted Average Shares |
|
—
|
59.25
+22.99%
|
48.18
+5.41%
|
45.70
|
| Diluted NI Availto Com Stockholders |
|
-81.27
+0.02%
|
-81.28
+24.94%
|
-108.30
+4.43%
|
-113.31
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
334.16
+23.64%
|
270.27
+20.07%
|
225.10
-23.10%
|
292.70
|
| Current Assets |
|
267.95
+31.99%
|
203.01
+38.35%
|
146.74
-26.52%
|
199.70
|
| Cash Cash Equivalents And Short Term Investments |
|
239.95
+29.70%
|
185.01
+62.03%
|
114.18
-31.90%
|
167.66
|
| Cash And Cash Equivalents |
|
124.25
+35.91%
|
91.42
+60.42%
|
56.98
-36.06%
|
89.13
|
| Cash Equivalents |
|
119.33
+32.20%
|
90.26
+69.24%
|
53.34
-36.14%
|
83.51
|
| Cash Financial |
|
4.92
+327.00%
|
1.15
-68.43%
|
3.65
-35.01%
|
5.62
|
| Other Short Term Investments |
|
115.71
+23.63%
|
93.59
+63.64%
|
57.20
-27.17%
|
78.53
|
| Receivables |
|
16.20
+99.05%
|
8.14
-54.09%
|
17.73
+6.54%
|
16.64
|
| Accounts Receivable |
|
16.20
+99.05%
|
8.14
-54.09%
|
17.73
+6.54%
|
16.64
|
| Inventory |
|
5.26
+32.22%
|
3.98
-29.77%
|
5.66
-11.33%
|
6.38
|
| Raw Materials |
|
5.26
+32.22%
|
3.98
-29.77%
|
5.66
-11.33%
|
6.38
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Current Deferred Assets |
|
0.89
-54.81%
|
1.96
-59.21%
|
4.81
+118.08%
|
2.21
|
| Other Current Assets |
|
5.65
+43.90%
|
3.93
-9.95%
|
4.36
-35.94%
|
6.81
|
| Total Non Current Assets |
|
66.21
-1.55%
|
67.25
-14.17%
|
78.36
-15.75%
|
93.00
|
| Net PPE |
|
59.93
-7.41%
|
64.73
-13.95%
|
75.22
-14.93%
|
88.42
|
| Gross PPE |
|
113.84
+2.78%
|
110.77
-1.88%
|
112.89
-2.13%
|
115.34
|
| Accumulated Depreciation |
|
-53.91
-17.10%
|
-46.04
-22.22%
|
-37.67
-39.89%
|
-26.93
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
56.98
+9.88%
|
51.86
+2.21%
|
50.74
+14.01%
|
44.50
|
| Construction In Progress |
|
0.06
-93.77%
|
0.90
-74.20%
|
3.48
-12.63%
|
3.99
|
| Other Properties |
|
15.12
-8.11%
|
16.45
-7.84%
|
17.85
-32.58%
|
26.48
|
| Leases |
|
41.69
+0.32%
|
41.56
+1.83%
|
40.81
+1.09%
|
40.37
|
| Other Non Current Assets |
|
6.28
+148.61%
|
2.53
-19.48%
|
3.14
-31.60%
|
4.59
|
| Total Liabilities Net Minority Interest |
|
72.98
+8.42%
|
67.31
-29.63%
|
95.66
+28.29%
|
74.56
|
| Current Liabilities |
|
39.63
+27.32%
|
31.13
-34.10%
|
47.23
+42.57%
|
33.13
|
| Payables And Accrued Expenses |
|
17.19
+120.46%
|
7.80
-47.74%
|
14.92
+1.66%
|
14.68
|
| Payables |
|
12.99
+103.05%
|
6.40
-57.12%
|
14.92
+14.97%
|
12.98
|
| Accounts Payable |
|
12.99
+103.05%
|
6.40
-57.12%
|
14.92
+16.07%
|
12.85
|
| Current Accrued Expenses |
|
4.20
+200.00%
|
1.40
|
0.00
-100.00%
|
1.70
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
7.34
-17.04%
|
8.85
-32.62%
|
13.13
+37.44%
|
9.55
|
| Total Tax Payable |
|
—
|
—
|
0.04
-69.92%
|
0.12
|
| Current Debt And Capital Lease Obligation |
|
8.08
-13.70%
|
9.37
-0.45%
|
9.41
+23.63%
|
7.61
|
| Current Debt |
|
1.19
-28.70%
|
1.67
+1.40%
|
1.65
-25.79%
|
2.22
|
| Other Current Borrowings |
|
1.19
-28.70%
|
1.67
+1.40%
|
1.65
-25.79%
|
2.22
|
| Current Capital Lease Obligation |
|
6.89
-10.45%
|
7.70
-0.84%
|
7.76
+43.96%
|
5.39
|
| Current Deferred Liabilities |
|
1.56
-49.61%
|
3.10
-5.72%
|
3.29
+154.10%
|
1.29
|
| Current Deferred Revenue |
|
1.56
-49.61%
|
3.10
-5.72%
|
3.29
+154.10%
|
1.29
|
| Other Current Liabilities |
|
5.46
+170.38%
|
2.02
-68.90%
|
6.49
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
33.35
-7.84%
|
36.19
-25.27%
|
48.42
+16.88%
|
41.43
|
| Long Term Debt And Capital Lease Obligation |
|
31.87
-8.65%
|
34.88
-8.97%
|
38.32
-6.63%
|
41.04
|
| Long Term Capital Lease Obligation |
|
31.87
-8.65%
|
34.88
-8.97%
|
38.32
-6.63%
|
41.04
|
| Other Non Current Liabilities |
|
1.48
+13.81%
|
1.30
-74.75%
|
5.16
+1226.74%
|
0.39
|
| Stockholders Equity |
|
261.19
+28.69%
|
202.96
+56.79%
|
129.44
-40.66%
|
218.14
|
| Common Stock Equity |
|
261.19
+28.69%
|
202.96
+56.79%
|
129.44
-40.66%
|
218.14
|
| Capital Stock |
|
0.01
+11.11%
|
0.01
+80.00%
|
0.01
+0.00%
|
0.01
|
| Common Stock |
|
0.01
+11.11%
|
0.01
+80.00%
|
0.01
+0.00%
|
0.01
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
102.48
+20.32%
|
85.17
+68.72%
|
50.48
+8.08%
|
46.71
|
| Ordinary Shares Number |
|
102.48
+20.32%
|
85.17
+68.72%
|
50.48
+8.08%
|
46.71
|
| Additional Paid In Capital |
|
892.33
+18.51%
|
752.96
+25.84%
|
598.36
+3.26%
|
579.46
|
| Retained Earnings |
|
-631.26
-14.78%
|
-549.99
-17.34%
|
-468.71
-30.05%
|
-360.41
|
| Gains Losses Not Affecting Retained Earnings |
|
0.10
+552.17%
|
-0.02
+89.64%
|
-0.22
+75.66%
|
-0.91
|
| Other Equity Adjustments |
|
0.10
+552.17%
|
-0.02
+89.64%
|
-0.22
+75.66%
|
-0.91
|
| Total Equity Gross Minority Interest |
|
261.19
+28.69%
|
202.96
+56.79%
|
129.44
-40.66%
|
218.14
|
| Total Capitalization |
|
261.19
+28.69%
|
202.96
+56.79%
|
129.44
-40.66%
|
218.14
|
| Working Capital |
|
228.32
+32.83%
|
171.89
+72.74%
|
99.51
-40.26%
|
166.57
|
| Invested Capital |
|
262.38
+28.22%
|
204.63
+56.10%
|
131.09
-40.51%
|
220.36
|
| Total Debt |
|
39.95
-9.72%
|
44.25
-7.29%
|
47.73
-1.90%
|
48.65
|
| Capital Lease Obligations |
|
38.76
-8.97%
|
42.58
-7.60%
|
46.08
-0.75%
|
46.43
|
| Net Tangible Assets |
|
261.19
+28.69%
|
202.96
+56.79%
|
129.44
-40.66%
|
218.14
|
| Tangible Book Value |
|
261.19
+28.69%
|
202.96
+56.79%
|
129.44
-40.66%
|
218.14
|
| Derivative Product Liabilities |
|
—
|
0.00
-100.00%
|
4.94
|
0.00
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-74.95
-65.99%
|
-45.15
+19.74%
|
-56.26
+19.90%
|
-70.23
|
| Cash Flow From Continuing Operating Activities |
|
-74.95
-65.99%
|
-45.15
+19.74%
|
-56.26
+19.90%
|
-70.23
|
| Net Income From Continuing Operations |
|
-81.27
+0.02%
|
-81.28
+24.94%
|
-108.30
+4.43%
|
-113.31
|
| Depreciation Amortization Depletion |
|
10.05
-8.18%
|
10.94
-3.14%
|
11.30
+33.97%
|
8.43
|
| Depreciation And Amortization |
|
10.05
-8.18%
|
10.94
-3.14%
|
11.30
+33.97%
|
8.43
|
| Other Non Cash Items |
|
1.03
-30.76%
|
1.49
-73.44%
|
5.62
+23.48%
|
4.55
|
| Stock Based Compensation |
|
9.43
-11.76%
|
10.69
-23.95%
|
14.05
-27.70%
|
19.43
|
| Asset Impairment Charge |
|
—
|
0.00
-100.00%
|
5.57
|
0.00
|
| Operating Gains Losses |
|
—
|
18.27
+353.79%
|
4.03
|
—
|
| Gain Loss On Investment Securities |
|
—
|
18.27
+353.79%
|
4.03
|
—
|
| Change In Working Capital |
|
-10.19
-293.25%
|
-2.59
-119.23%
|
13.48
+27.06%
|
10.61
|
| Change In Receivables |
|
-8.06
-184.08%
|
9.59
+981.43%
|
-1.09
-159.62%
|
1.82
|
| Changes In Account Receivables |
|
-8.06
-184.08%
|
9.59
+981.43%
|
-1.09
-159.62%
|
1.82
|
| Change In Inventory |
|
-0.20
-104.61%
|
4.42
+328.80%
|
-1.93
+35.14%
|
-2.98
|
| Change In Prepaid Assets |
|
-2.22
-295.26%
|
1.14
-69.61%
|
3.75
+674.38%
|
0.48
|
| Change In Payables And Accrued Expense |
|
6.86
+160.54%
|
-11.32
-291.30%
|
5.92
+267.70%
|
1.61
|
| Change In Accrued Expense |
|
2.31
+196.04%
|
-2.40
-423.58%
|
0.74
+150.17%
|
-1.48
|
| Change In Payable |
|
4.55
+150.99%
|
-8.92
-272.34%
|
5.18
+67.63%
|
3.09
|
| Change In Account Payable |
|
4.55
+150.99%
|
-8.92
-272.34%
|
5.18
+67.63%
|
3.09
|
| Change In Other Working Capital |
|
-1.54
+62.63%
|
-4.12
-169.15%
|
5.95
+318.98%
|
-2.72
|
| Change In Other Current Liabilities |
|
-5.02
-117.79%
|
-2.31
-360.75%
|
0.88
-92.87%
|
12.39
|
| Investing Cash Flow |
|
-22.57
+35.65%
|
-35.07
-367.72%
|
13.10
-75.07%
|
52.54
|
| Cash Flow From Continuing Investing Activities |
|
-22.57
+35.65%
|
-35.07
-367.72%
|
13.10
-75.07%
|
52.54
|
| Net PPE Purchase And Sale |
|
-4.50
-230.93%
|
-1.36
+87.53%
|
-10.91
+78.13%
|
-49.90
|
| Purchase Of PPE |
|
-4.50
-180.97%
|
-1.60
+85.31%
|
-10.91
+78.13%
|
-49.90
|
| Sale Of PPE |
|
0.00
-100.00%
|
0.24
|
0.00
|
—
|
| Capital Expenditure |
|
-4.50
-180.97%
|
-1.60
+85.31%
|
-10.91
+78.13%
|
-49.90
|
| Net Investment Purchase And Sale |
|
-18.06
+46.41%
|
-33.71
-240.39%
|
24.01
-76.56%
|
102.43
|
| Purchase Of Investment |
|
-210.17
-72.69%
|
-121.71
-17.09%
|
-103.94
+14.44%
|
-121.49
|
| Sale Of Investment |
|
192.11
+118.31%
|
88.00
-31.23%
|
127.95
-42.86%
|
223.92
|
| Financing Cash Flow |
|
130.34
+13.66%
|
114.67
+939.54%
|
11.03
+707.54%
|
1.37
|
| Cash Flow From Continuing Financing Activities |
|
130.34
+13.66%
|
114.67
+939.54%
|
11.03
+707.54%
|
1.37
|
| Net Issuance Payments Of Debt |
|
0.58
+151.77%
|
-1.13
-749.43%
|
0.17
+115.83%
|
-1.10
|
| Issuance Of Debt |
|
2.59
|
0.00
-100.00%
|
3.44
+187.94%
|
1.19
|
| Repayment Of Debt |
|
-2.00
-77.17%
|
-1.13
+65.38%
|
-3.26
-42.35%
|
-2.29
|
| Long Term Debt Issuance |
|
2.59
|
0.00
-100.00%
|
3.44
+187.94%
|
1.19
|
| Long Term Debt Payments |
|
-2.00
-77.17%
|
-1.13
+65.38%
|
-3.26
-42.35%
|
-2.29
|
| Net Long Term Debt Issuance |
|
0.58
+151.77%
|
-1.13
-749.43%
|
0.17
+115.83%
|
-1.10
|
| Net Common Stock Issuance |
|
126.80
+29.62%
|
97.82
+2684.63%
|
3.51
|
0.00
|
| Proceeds From Stock Option Exercised |
|
3.15
-83.63%
|
19.21
+161.55%
|
7.34
+197.93%
|
2.46
|
| Net Other Financing Charges |
|
-0.19
+84.63%
|
-1.23
|
—
|
—
|
| Changes In Cash |
|
32.82
-4.73%
|
34.45
+207.24%
|
-32.13
-96.74%
|
-16.33
|
| Effect Of Exchange Rate Changes |
|
0.01
+127.27%
|
-0.02
-37.50%
|
-0.02
+87.40%
|
-0.13
|
| Beginning Cash Position |
|
93.20
+58.58%
|
58.77
-35.35%
|
90.92
-15.33%
|
107.38
|
| End Cash Position |
|
126.03
+35.22%
|
93.20
+58.58%
|
58.77
-35.35%
|
90.92
|
| Free Cash Flow |
|
-79.45
-69.94%
|
-46.75
+30.39%
|
-67.17
+44.09%
|
-120.13
|
| Interest Paid Supplemental Data |
|
—
|
—
|
0.00
|
0.00
|
| Income Tax Paid Supplemental Data |
|
0.02
-39.47%
|
0.04
-40.63%
|
0.06
+36.17%
|
0.05
|
| Amortization Of Securities |
|
-3.99
-49.64%
|
-2.67
-33.35%
|
-2.00
-3608.77%
|
0.06
|
| Common Stock Issuance |
|
126.80
+29.62%
|
97.82
+2684.63%
|
3.51
|
0.00
|
| Issuance Of Capital Stock |
|
126.80
+29.62%
|
97.82
+2684.63%
|
3.51
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-03-17 View
- 42026-03-17 View
- 42026-03-17 View
- 42026-03-17 View
- 8-K2026-03-17 View
- 10-K2026-02-26 View
- 8-K2026-02-26 View
- 42026-02-25 View
- 42026-02-25 View
- 42026-02-25 View
- 42026-02-25 View
- 42026-02-13 View
- 42026-01-23 View
- 8-K2026-01-08 View
- 8-K2025-11-28 View
- 42025-11-28 View
- 8-K2025-11-25 View
- 8-K2025-11-10 View
- 42025-11-05 View
- 10-Q2025-11-04 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|